Merck & Co. Patent-Cliff Exposure & CMS Drug Spending Portfolio
Merck & Co. (Rahway, NJ): 59 reconciled FDA prescription therapies (76.5% 2025 to 2030 cliff risk), $8.38B 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Rahway, NJ |
| Reconciled FDA Portfolio Therapies | 59 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 76.5% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $8.38B |
| 2024 Medicare Part D Spend | $6.30B |
| 2024 Medicaid Spend | $2.08B |
| California HCAI SB 17 Filings | 24 WAC filings (max 32.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.